Travere Therapeutics Statistics
Travere Therapeutics (17R) Stock Statistics & Valuation Metrics
Total Valuation
Travere Therapeutics has a market cap or net worth of EUR 4.47B. The enterprise value is EUR 5.72B.
- Market Cap
- EUR 4.47B
- Enterprise Value
- EUR 5.72B
Share Statistics
Travere Therapeutics has 95,992,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 95,992,160
- Owned by Insiders
- 1.47%
- Owned by Institutions
- 62.57%
Financial Efficiency
Travere Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -13.95%.
- Return on Equity (ROE)
- -0.22
- Return on Assets (ROA)
- -0.04
- Return on Invested Capital (ROIC)
- -13.95%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 987.38K
- Profits Per Employee
- -51.40K
- Employee Count
- 497
- Asset Turnover
- 0.81
- Inventory Turnover
- 1.76
Valuation Ratios
The current PE Ratio of Travere Therapeutics is -33.33. Travere Therapeutics’s PEG ratio is 0.29.
- PE Ratio
- -33.33
- PS Ratio
- 7.67
- PB Ratio
- 217.84
- Price to FCF
- 36.82
- Price to Operating Cash Flow
- 27.86
- PEG Ratio
- 0.29
Income Statement
In the last 12 months, Travere Therapeutics had revenue of 490.73M and earned -25.55M in profits. Earnings per share was -0.56.
- Revenue
- 490.73M
- Gross Profit
- 480.39M
- Operating Income
- -62.82M
- Pretax Income
- -49.27M
- Net Income
- -25.55M
- EBITDA
- 22.22M
- Earnings Per Share (EPS)
- -0.56
Cash Flow
In the last 12 months, operating cash flow was 176.59M and capital expenditures -41.04M, giving a free cash flow of 135.54M billion.
- Operating Cash Flow
- 176.59M
- Free Cash Flow
- 135.54M
- Free Cash Flow per Share
- 1.43
Dividends & Yields
Travere Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.81%
- Earnings Yield
- -2.56%
Stock Price Statistics
- Beta
- 1.39
- 52-Week Price Change
- 10.74%
- 50-Day Moving Average
- 33.00
- 200-Day Moving Average
- 33.00
- Relative Strength Index (RSI)
- 63.30
- Average Volume (3m)
- ―
Important Dates
Travere Therapeutics upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 02, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Travere Therapeutics as a current ratio of 2.74, with Debt / Equity ratio of 286.28%
- Current Ratio
- 2.74
- Quick Ratio
- 2.70
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- 10.61
- Interest Coverage Ratio
- -5.85
Taxes
In the past 12 months, Travere Therapeutics has paid 988.00K in taxes.
- Income Tax
- 988.00K
- Effective Tax Rate
- -0.02
Enterprise Valuation
Travere Therapeutics EV to EBITDA ratio is -54.17, with an EV/FCF ratio of 39.19.
- EV to Sales
- 8.16
- EV to EBITDA
- -54.17
- EV to Free Cash Flow
- 39.19
- EV to Operating Cash Flow
- 30.08
Balance Sheet
Travere Therapeutics has EUR 471.82M in cash and marketable securities with EUR 616.15M in debt, giving a net cash position of -EUR 144.34M billion.
- Cash & Marketable Securities
- EUR 471.82M
- Total Debt
- EUR 616.15M
- Net Cash
- -EUR 144.34M
- Net Cash Per Share
- -EUR 1.50
- Tangible Book Value Per Share
- -EUR 1.50
Margins
Gross margin is 94.72%, with operating margin of -20.50%, and net profit margin of -18.66%.
- Gross Margin
- 94.72%
- Operating Margin
- -20.50%
- Pretax Margin
- -24.53%
- Net Profit Margin
- -18.66%
- EBITDA Margin
- -15.06%
- EBIT Margin
- -23.17%
Analyst Forecast
The average price target for Travere Therapeutics is EUR 64.96, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 64.96
- Price Target Upside
- 96.84% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 12
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 5
- AI Score
- ―
